Cannabis original products discount agreements
Original notice title
Germany – Pharmaceutical products – Open-House-Originale-Rabattverträge 2026-01 - Cannabis
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
60 / 100
Risk factors
The notice states that this is not a public procurement subject to procurement law. Disputes are handled by social cour...
No estimated value or guaranteed volume. Revenues are uncertain and depend on actual prescriptions and market uptake.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- Techniker Krankenkasse
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Mar 30, 2028
Overview
Moderate opportunityKey Facts
- Supplies contract
- 2 lots
- Duration until Mar 2028
- Conclusion of discount agreements for cannabis-based pharmaceutical products (cannabis extracts and dronabinol)
- Contract duration up to 24 months, starting April 2026, ending March 2028
Show full summary
This is an Open House procedure for concluding discount agreements (Rabattverträge) for cannabis pharmaceutical products with eligible pharmaceutical entrepreneurs. The tender involves two lots: cannabis extracts (oral use) and dronabinol. The procedure is open to all eligible suppliers throughout the contract duration (April 2026 to March 2028). No estimated contract value is provided, and no award criteria are specified beyond meeting eligibility requirements. The contracting authority is Techniker Krankenkasse, with other participating health insurers.
Risks
The notice states that this is not a public procurement subject to procurement law. Disputes are handled by social cour...
No estimated value or guaranteed volume. Revenues are uncertain and depend on actual prescriptions and market uptake.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur (pharmazeutischer Unternehmer) as per §4 Abs. 18 AMG
- Valid marketing authorization for the offered medicinal products under §21 AMG
- Registered seat in Germany, EU, or EEA
Requirements may be incomplete.
Buyer
Location
Hamburg, DEU
Website
Identifier
992-80116-93
Activity
Health
Lots (2)
LOT-0001
Cannabis Extracts (Oral Use)
Conclusion of discount agreements for cannabis extracts (THC+CBD) for oral application under §130a Abs. 8 SGB V in an Open House procedure.
Location
Duration
Category
Deadline
Award details
Ziel ist der Abschluss von Arzneimittelrabattverträgen nach § 130a Abs. 8 i.V.m. § 31 Absatz 6 SGB VSGB V zu Cannabis im Rahmen eines Open-House-Verfahrens.
Value note
Show original TED data
Original lot title
Cannabisextrakte (zur oralen Anwendung)
Original TED description
Ziel ist der Abschluss von Arzneimittelrabattverträgen nach § 130a Abs. 8 i.V.m. § 31 Absatz 6 SGB VSGB V zu Cannabis im Rahmen eines Open-House-Verfahrens.
LOT-0002
Dronabinol
Conclusion of discount agreements for dronabinol under §130a Abs. 8 SGB V in an Open House procedure.
Location
Duration
Category
Deadline
Award details
Ziel ist der Abschluss von Arzneimittelrabattverträgen nach § 130a Abs. 8 i.V.m. § 31 Absatz 6 SGB VSGB V zu Cannabis im Rahmen eines Open-House-Verfahrens.
Value note
Show original TED data
Original TED description
Ziel ist der Abschluss von Arzneimittelrabattverträgen nach § 130a Abs. 8 i.V.m. § 31 Absatz 6 SGB VSGB V zu Cannabis im Rahmen eines Open-House-Verfahrens.
Procurement Details
- Publication date
- 16 Feb 2026
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 113323-2026
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
60 / 100
Risk factors
The notice states that this is not a public procurement subject to procurement law. Disputes are handled by social cour...
No estimated value or guaranteed volume. Revenues are uncertain and depend on actual prescriptions and market uptake.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications